Ticker Details
Neurocrine Biosciences, Inc. Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
IPO Date:	May 23, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$18.15B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.00 | 2.18%
Avg Daily Range (30 D):	$2.85 | 1.75%
Avg Daily Range (90 D):	$2.16 | 1.47%

Institutional Daily Volume
Avg Daily Volume:	.7M
Avg Daily Volume (30 D):	.85M
Avg Daily Volume (90 D):	.89M

Trade Size
Avg Trade Size (Sh.):	90
Avg Trade Size (Sh.) (30 D):	42
Avg Trade Size (Sh.) (90 D):	44

Institutional Trades
Total Institutional Trades:	12,455
Avg Institutional Trade:	$4.16M
Avg Institutional Trade (30 D):	$15.19M
Avg Institutional Trade (90 D):	$11.65M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$9.99M
Avg Closing Trade (30 D):	$43.95M
Avg Closing Trade (90 D):	$32.87M
Avg Closing Volume:	102.7K

News

Jun 10, 2026 @ 8:44 PM Tom Lee's Small-Cap Granny Shots ETF Reloads: Firs... Source: Chandrima Sanyal

May 1, 2026 @ 6:36 AM Nxera Pharma Operational Highlights and Consolidat... Source: Nxera Pharma

Apr 12, 2026 @ 11:30 PM Nxera Pharma’s Partner Neurocrine Bioscienc... Source: Na

Apr 6, 2026 @ 8:20 PM Why Soleno Therapeutics Stock Rocketed Higher on M... Source: Eric Volkman

Apr 6, 2026 @ 12:13 PM Neurocrine Buys Soleno To Tap High-Growth Rare Dis... Source: Vandana Singh

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$6.71	$1.97	$1.54
Diluted EPS	$6.49	$1.91	$1.48
Revenue	$3.1B	$814.5M	$805.5M
Gross Profit	$3.05B	$800.7M	$787.9M
Net Income / Loss	$668.6M	$197.9M	$153.7M
Operating Income / Loss	$788.9M	$193.4M	$210.9M
Cost of Revenue	$56.7M	$13.8M	$17.6M
Net Cash Flow	$72.4M	$-446.5M	$372.8M
PE Ratio